Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal lung disease characterized by
the expansion of the fibroblast/myofibroblast population and aberrant remodeling. However …

Transforming growth factor-β (TGF-β) is central during the pathogenesis of pulmonary
fibrosis, in which the plasminogen activator inhibitor-1 (PAI-1) also has an established role …

Radiation‐induced lung injury (RILI) mainly contributes to the complications of thoracic
radiotherapy. RILI can be divided into radiation pneumonia (RP) and radiation‐induced lung …

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with a poor prognosis
and limited treatment options. Many compounds have shown efficacy in preclinical models …

Idiopathic pulmonary fibrosis (IPF) affects over 500,000 people in the United States and
Europe alone. The disease is characterized by progressive obliteration of normal alveolar …

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary
disease with a median survival of 2–4 years after diagnosis. A significant number of IPF …

Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of
idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low …

Idiopathic pulmonary fibrosis (IPF) is a poorly understood disease that usually leads to death
within 5 years of diagnosis. Despite our better understanding of IPF pathogenesis, the …

The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from
chronic inflammation to aberrant wounding healing and even more to the current paradigms …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive diffuse parenchymal lung
disease of unknown origin, with a mortality rate exceeding that of many cancers. The …